Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter
Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter
贝尔·波特将Paradigm Biopharmaceuticals的目标股价下调了66%,至每股0.47澳元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册